2026 Pharma Physicians 
World of DTC Marketing
JULY 28, 2022
Still, the pharma industry is fighting hard to keep it off the table. Late last year, the Senate Finance Committee released draft legislation enabling Medicare negotiation for up to 10 drugs in 2025, 15 in 2026 and 2027, and 20 in 2028 and beyond. Pharma is a very profitable industry. The secretary of the U.S.
World of DTC Marketing
OCTOBER 27, 2020
Our healthcare system makes too much money for insurers, PBM’s and pharma companies to change. By 2026, national health expenditures will reach $5.7 It’s simple: people trust each other more than pharma companies who they view with a high degree of skepticism. It’s a good read but ignores a simple fact.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
MAY 12, 2021
Billion by 2026 with a CAGR of 37.2% Physicians and patients raise legitimate questions and concerns about the safety, effectiveness, and accessibility of telehealth. Wearable technology allows physicians to check in on the health of their patients in between physical office visits. Billion in 2019 and Expected to Reach USD 171.81
Clarivate
APRIL 24, 2023
Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. VillageMD’s rollup continued with a March 3 announcement that it was acquiring Starling Physicians, a Connecticut-based physician group, expanding its footprint to 680 practice locations in 26 markets.
PM360
APRIL 7, 2023
Dan Renick The IRA presents market access teams with a unique opportunity to make recommendations to CMS regarding the evidence and methodology that will be applied in evaluating drugs for upcoming Medicare negotiations that will lead to price adjustments in 2026. Quality and value measurements commonly used outside of the U.S.
Clarivate
OCTOBER 25, 2023
The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.
PM360
APRIL 7, 2023
No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.
Expert insights. Personalized for you.
256 
Let's personalize your content